AMP Practice Guidelines
Collapse AMP/ASCO/CAP Standards and Guidelines of Somatic Variant Interpretation and Reporting (CE available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

In January 2017, a working group comprised of representatives from the Association for Molecular Pathology (AMP), College of American Pathologists (CAP), American Society of Clinical Oncology (ASCO), and American College of Medical Genetics and Genomics (ACMG) published the guidelines for the interpretation and reporting of somatic variants. This subject matter expert panel comprised of investigators with expertise in molecular pathology, medical genetics, and clinical oncology, assessed the current status of NGS-based testing for cancer and established standardized classification, annotation, interpretation, and reporting conventions for sequence variants associated with cancer.

In this webinar, Dr. Marilyn M. Li summarizes the guideline and provides a number of examples illustrating how to implement the classification system.


Practice Guideline Available Here

Speaker: Marilyn M. Li, MD

Host: Antonia R. Sepulveda, MD, PhD

Duration: 1 hr

Level of Instruction: Basic

 

Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase Webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by January 26, 2021

 

You may also be interested in:

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Formats Available: Streaming
Original Course Date: January 26, 2018
MORE INFOMORE INFO AMP/ASCO/CAP Standards and Guidelines of Somatic Variant Interpretation and Reporting (CE available)
Collapse Interpretation and Reporting of Sequence Variants — Inherited Conditions (CE available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

The webinar covers the development of the publication "AMP/ACMG Standards and Guidelines for the Interpretation of Sequence Variants". Attendees will learn how to apply the guidelines to classify individual sequence variants.


Practice Guideline Available Here

Speaker: Elaine B. Spector, PhD, FACMG

Host: Kristy Crooks, PhD

Duration: 1 hr

Level of Instruction: Basic

If you would like continuing education credit, click on the links below.

Credit Type

Number of Credit Hours

Click on link to purchase:

CME/CMLE

1.0

Purchase webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM

1.0

Purchase webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by June 29, 2020.

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Formats Available: Streaming
Original Course Date: June 29, 2017
MORE INFOMORE INFO Interpretation and Reporting of Sequence Variants — Inherited Conditions (CE available)
Collapse Molecular Biomarkers for the Evaluation of Colorectal Cancer (CE available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

In this webinar, Antonia Sepulveda provides an overview of the American Society of Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO)'s evidence-based practice guideline on molecular marker testing for patients with colorectal carcinoma that identifies opportunities for improving patient outcomes.

The guideline addresses a wide range of molecular markers appropriate for testing in patients with early and advanced colorectal cancer which aids in establishing standard molecular marker testing to help guide targeted therapy decisions and advance personalized care for colorectal cancer patients.


Practice Guideline Available Here

Speaker: Antonia R. Sepulveda MD, PhD

Duration: 1.0 hr

Level of Instruction: Basic

If you would like continuing education credit, click on the links below.

Credit Type

Number of Credit Hours

Click on link to purchase:

CME/CMLE

1.0

Purchase webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM

1.0

Purchase webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by March 31, 2020

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Formats Available: Streaming
Original Course Date: March 31, 2017
MORE INFOMORE INFO Molecular Biomarkers for the Evaluation of Colorectal Cancer (CE available)
Collapse Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision (CE Available)

   

This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA. If you would like continuing education credit for the webinar, click on the links in the table below to access the webinar + CME/CMLE or webinar + SAM.


Speaker:

Neal Lindeman, MD

Moderator:

Anna Yemelyanova, MD


The advent of targeted therapies based on predictive biomarkers has dramatically altered the role of the molecular pathologist in lung cancer patient care. This webinar reviews the new recommendations published in the revised 2018 CAP/IASLC/AMP lung cancer predictive biomarker guidelines (Lindeman et al., J Mol Diagn, 2018). This webinar, reviewing the evidence and logic behind the new recommendations, is designed for molecular pathologists, pathologists, oncologists, clinicians, trainees, and multidisciplinary tumor boards to help improve NSCLC patient care. Topics to be covered include recommendations regarding new predictive biomarkers; recommendations for testing for EGFR and ALK TKI resistance; and recommendations regarding new testing methodologies including the use of multiplexed genetic sequencing panels (e.g., NGS testing) to identify other treatment options beyond EGFR, ALK, and ROS1 as well as cell-free circulating DNA testing for EGFR resistance mutations. The revised 2018 CAP/IASLC/AMP lung cancer predictive biomarker guidelines will impact the daily practice of molecular pathologists and clinicians in the care of nearly 150,000 eligible lung cancer patients each year, regardless of whether in a community practice, a large reference lab, or an academic setting, and regardless of their level of expertise or experience.

This webinar is part 1 of a five-part series aimed a breaking down barriers to NSCLC testing and treatment. If you'd like more information about the series go here


Practice Guideline Available Here

Duration: 1 hr

Level of Instruction: Basic

Supported by an educational grant from AstraZeneca


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Free for all)

SAM 1.0

Purchase Webinar + SAM

(Free for all)

Continuing Education Credit must be purchased and claimed by May 29, 2021

 

You may also be interested in:

 

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

   

Formats Available: Lindeman Presentation
Original Course Date: May 29, 2018
On-Demand Release Date: Available Now
MORE INFOMORE INFO Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision (CE Available)
Collapse Mutational Pattern Recognition in Chronic Myeloid Neoplasms (CMNs) (CE available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

This presentation summarizes the findings of the Association for Molecular Pathology Chronic Myeloid Neoplasm Working Group. Chronic myeloid neoplasms (CMNs) are defined as a complex group of hematopoietic disorders, encompassing myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), the overlap entities (MDS/MPNs), and systemic mastocytosis. The goal of this group was to distill the vast amounts of literature on the mutational profiles of the CMNs into high impact information that would aid molecular pathologists in the development of next generation sequencing (NGS) myeloid panels. This work identifies 34 genes as the minimum recommended testing list and provides information on the frequency of these genes in the various CMNs as well as their prognostic and therapeutic import. In addition, the findings highlight the recurrent patterns of mutational clonal evolution in these patients, uncovering critical insight into the biology of these neoplasms.


Practice Guideline Available Here

Speaker: Annette S. Kim, MD, PhD

Moderator: Todd W. Kelley, MD

Duration: 1 hr

Level of Instruction: Intermediate


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase Webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by July 19, 2021

You may also be interested in:

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Formats Available: Kim Presentation
Original Course Date: July 19, 2018
MORE INFOMORE INFO Mutational Pattern Recognition in Chronic Myeloid Neoplasms (CMNs) (CE available)
Collapse Practical Considerations for the Validation of Next-Generation Sequencing-Based Oncology Panels (CE Available)

   This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


                                                                  

Speaker:
Lawrence J. Jennings, MD, PhD


Moderator: 
Antonia R. Sepulveda, MD, PhD

 

 

Description: Validation of NGS-based testing for oncology panels can be challenging given the many steps and wide range of targeted mutations. In this presentation, Dr. Jennings will discuss the recent AMP/CAP guideline recommendations for validation and review practical ways to provide documented evidence with the clinical NGS reports.


Practice Guideline Available Here

Duration: 1 hr

Level of Instruction: Basic


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase Webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by April 25, 2021

 

You may also be interested in:

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Formats Available: Jennings Webinar
Original Course Date: April 25, 2018
MORE INFOMORE INFO Practical Considerations for the Validation of Next-Generation Sequencing-Based Oncology Panels (CE Available)
Collapse Recommendations for Clinical <i>CYP2C19</i> Genotyping Allele Selection (CE available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

In this webinar, Dr. Karen Weck will present the recommendations of The AMP Pharmacogenomics Working Group of the Clinical Practice Committee for inclusion of variants in CYP2C19 genotyping panels. The working group has published consensus, evidence-based recommendations using criteria such as allele function, population frequency, and availability of reference materials. The recommendations include a Tier 1 minimum set of alleles and defining variants that should be included in all clinical CYP2C19 PGx tests, and a Tier 2 list of additional optional alleles that do not currently meet all of the criteria for inclusion in Tier 1. These recommendations are intended to aid clinical laboratory professionals when designing and validating CYP2C19 genotyping assays, promote standardization of testing across different laboratories, and complement existing clinical guidelines for pharmacogenetic testing.


Practice Guideline Available Here

Speaker: Karen E. Weck, MD

Host: Joshua Deignan, PhD

Duration: 1 hr

Level of Instruction: Basic

 

Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase Webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by March 21, 2021

 

You may also be interested in:

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Formats Available: Weck Presentation
Original Course Date: March 21, 2018
MORE INFOMORE INFO Recommendations for Clinical <i>CYP2C19</i> Genotyping Allele Selection (CE available)
Collapse Standards and Guidelines for Validating Next Generation Sequencing Bioinformatics Pipelines: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists (CE Available)

This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


Description:

Bioinformatics pipelines are integral components of next-generation sequencing (NGS) assays. Until recently, a lack of guidelines caused significant variability in how pipelines were validated in the molecular genetics and pathology community. To address this important issue, Association for Molecular Pathology (AMP) with liaison representation from the College of American Pathologists (CAP), and the American Medical Informatics Association (AMIA) released Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines in January 2018. In this webinar, Dr. Somak Roy and Dr. Alexis Carter will highlight some of the important recommendations.


Practice Guideline Available Here

Speakers: Somak Roy, MD and Alexis B. Carter, MD

Moderator: Justin Zook, PhD

Duration: 1 hr

Level of Instruction: Basic

 

Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Just $5.00 USD for AMP members)

SAM 1.0

Purchase Webinar + SAM

(Just $10.00 USD for AMP members)

Continuing Education Credit must be purchased and claimed by April 20, 2021

 

You may also be interested in:

 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Formats Available: Roy and Carter Presentation
Original Course Date: April 20, 2018
MORE INFOMORE INFO Standards and Guidelines for Validating Next Generation Sequencing Bioinformatics Pipelines: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists (CE Available)
Collapse The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer

Recent definitions for clinical utility of molecular tests focus on whether a test result will alter treatment. This definition neglects other uses of molecular testing to diagnose disease, manage symptoms, prognosticate or predict future disease. The fullest realization of precision medicine will require embracing all aspects of clinical utility. This three-part webinar series, supported by AMP, presents the discussions of AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility (FEND) working group, and its resulting publication, “The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology” (Joseph L, et al. J Mol Diagn. 2016;18[5]:605–619).

 

Part 1 - An Overview of AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility

Speakers: Loren Joseph, MD; Elaine Lyon, PhD

Host: Roger Klein, MD, JD

 

Part 2 - AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility – Oncology Cases

Speakers: Pranil Chandra, DO, FCAP, FASP; Rajyasree Emmadi, MD, FCAP

Host: Loren Joseph, MD

 

Part 3: AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility – Inherited Conditions

Speakers: Stephanie Hallam, PhD, FACMG, MBA; Victoria Pratt, PhD, FACMG

Host: Elaine Lyon, PhD

Practice Guideline Available Here

Total Duration: 3 hr

 

All sales are final. No refunds will be issued.

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

Formats Available: Streaming
Original Course Date: September 28, 2016
MORE INFOMORE INFO The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer